Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EBT (2016 - 2025)

Historic EBT for KalVista Pharmaceuticals (KALV) over the last 9 years, with Q2 2025 value amounting to -$53.1 million.

  • KalVista Pharmaceuticals' EBT fell 1888.51% to -$53.1 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$167.2 million, marking a year-over-year decrease of 7670.23%. This contributed to the annual value of -$180.1 million for FY2025, which is 4217.18% down from last year.
  • KalVista Pharmaceuticals' EBT amounted to -$53.1 million in Q2 2025, which was down 1888.51% from -$40.4 million recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' EBT ranged from a high of -$29.0 million in Q1 2024 and a low of -$53.1 million during Q2 2025